Financial - Capital Markets
Compare Stocks
4 / 10Stock Comparison
MKTX vs JPM vs ICE vs CME
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Diversified
Financial - Data & Stock Exchanges
Financial - Data & Stock Exchanges
MKTX vs JPM vs ICE vs CME — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Financial - Capital Markets | Banks - Diversified | Financial - Data & Stock Exchanges | Financial - Data & Stock Exchanges |
| Market Cap | $5.53B | $849.03B | $86.89B | $104.61B |
| Revenue (TTM) | $817M | $270.79B | $12.64B | $6.52B |
| Net Income (TTM) | $220M | $58.03B | $3.30B | $4.24B |
| Gross Margin | 68.9% | 58.6% | 61.9% | 86.1% |
| Operating Margin | 41.7% | 27.7% | 38.7% | 64.9% |
| Forward P/E | 18.2x | 14.2x | 19.1x | 23.6x |
| Total Debt | $73M | $751.15B | $20.28B | $3.76B |
| Cash & Equiv. | $544M | $469.32B | $837M | $4.42B |
MKTX vs JPM vs ICE vs CME — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MarketAxess Holding… (MKTX) | 100 | 29.3 | -70.7% |
| JPMorgan Chase & Co. (JPM) | 100 | 323.6 | +223.6% |
| Intercontinental Ex… (ICE) | 100 | 157.7 | +57.7% |
| CME Group Inc. (CME) | 100 | 157.9 | +57.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MKTX vs JPM vs ICE vs CME
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MKTX lags the leaders in this set but could rank higher in a more targeted comparison.
JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 14 yrs, beta 1.00, yield 1.6%
- Rev growth 14.6%, EPS growth 21.7%
- 471.7% 10Y total return vs CME's 291.2%
- PEG 1.09 vs MKTX's 2.95
ICE is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.33, Low D/E 69.9%, current ratio 1.02x
- Beta 0.33 vs JPM's 1.00, lower leverage
CME is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta -0.30, yield 3.8%, current ratio 92.97x
- Efficiency ratio 0.2% vs JPM's 0.3% (lower = leaner)
- 3.8% yield, 6-year raise streak, vs JPM's 1.6%
- Efficiency ratio 0.2% vs JPM's 0.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.6% NII/revenue growth vs CME's 6.4% | |
| Value | Lower P/E (14.2x vs 23.6x), PEG 1.09 vs 1.72 | |
| Quality / Margins | Efficiency ratio 0.2% vs JPM's 0.3% (lower = leaner) | |
| Stability / Safety | Beta 0.33 vs JPM's 1.00, lower leverage | |
| Dividends | 3.8% yield, 6-year raise streak, vs JPM's 1.6% | |
| Momentum (1Y) | +28.7% vs MKTX's -33.6% | |
| Efficiency (ROA) | Efficiency ratio 0.2% vs JPM's 0.3% |
MKTX vs JPM vs ICE vs CME — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MKTX vs JPM vs ICE vs CME — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
CME leads 1 • MKTX leads 1 • ICE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CME leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $270.8B annually — 331.4x MKTX's $817M. CME is the more profitable business, keeping 62.0% of every revenue dollar as net income compared to JPM's 21.6%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $817M | $270.8B | $12.6B | $6.5B |
| EBITDAEarnings before interest/tax | $429M | $81.3B | $6.5B | $4.7B |
| Net IncomeAfter-tax profit | $220M | $58.0B | $3.3B | $4.2B |
| Free Cash FlowCash after capex | $346M | -$119.7B | $4.3B | $4.4B |
| Gross MarginGross profit ÷ Revenue | +68.9% | +58.6% | +61.9% | +86.1% |
| Operating MarginEBIT ÷ Revenue | +41.7% | +27.7% | +38.7% | +64.9% |
| Net MarginNet income ÷ Revenue | +33.6% | +21.6% | +26.1% | +62.0% |
| FCF MarginFCF ÷ Revenue | +45.9% | -15.5% | +33.9% | +64.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.2% | +16.0% | +23.1% | +21.4% |
Valuation Metrics
JPM leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 15.9x trailing earnings, JPM trades at a 40% valuation discount to ICE's 26.6x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 1.23x vs MKTX's 3.32x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $5.5B | $849.0B | $86.9B | $104.6B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $1.13T | $106.3B | $103.9B |
| Trailing P/EPrice ÷ TTM EPS | 20.45x | 15.94x | 26.59x | 25.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.16x | 14.17x | 19.14x | 23.61x |
| PEG RatioP/E ÷ EPS growth rate | 3.32x | 1.23x | 2.99x | 1.88x |
| EV / EBITDAEnterprise value multiple | 12.00x | 13.62x | 16.47x | 23.08x |
| Price / SalesMarket cap ÷ Revenue | 6.77x | 3.14x | 6.88x | 16.04x |
| Price / BookPrice ÷ Book value/share | 4.04x | 2.63x | 3.02x | 3.62x |
| Price / FCFMarket cap ÷ FCF | 14.73x | — | 20.26x | 24.95x |
Profitability & Efficiency
MKTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $12 for ICE. MKTX carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.18x. On the Piotroski fundamental quality scale (0–9), ICE scores 9/9 vs CME's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +15.8% | +16.1% | +11.6% | +15.3% |
| ROA (TTM)Return on assets | +10.9% | +1.3% | +2.3% | +2.2% |
| ROICReturn on invested capital | +18.0% | +5.4% | +7.5% | +10.2% |
| ROCEReturn on capital employed | +23.0% | +8.2% | +9.5% | +3.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 9 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 2.18x | 0.70x | 0.13x |
| Net DebtTotal debt minus cash | -$472M | $281.8B | $19.4B | -$666M |
| Cash & Equiv.Liquid assets | $544M | $469.3B | $837M | $4.4B |
| Total DebtShort + long-term debt | $73M | $751.1B | $20.3B | $3.8B |
| Interest CoverageEBIT ÷ Interest expense | 443.10x | 0.74x | 6.53x | 41.55x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,034 today (with dividends reinvested), compared to $3,723 for MKTX. Over the past 12 months, JPM leads with a +28.7% total return vs MKTX's -33.6%. The 3-year compound annual growth rate (CAGR) favors JPM at 34.0% vs MKTX's -19.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -16.2% | -2.3% | -3.8% | +9.7% |
| 1-Year ReturnPast 12 months | -33.6% | +28.7% | -11.3% | +5.9% |
| 3-Year ReturnCumulative with dividends | -47.3% | +140.8% | +48.2% | +72.2% |
| 5-Year ReturnCumulative with dividends | -62.8% | +110.3% | +42.4% | +64.1% |
| 10-Year ReturnCumulative with dividends | +37.2% | +471.7% | +222.9% | +291.2% |
| CAGR (3Y)Annualised 3-year return | -19.2% | +34.0% | +14.0% | +19.9% |
Risk & Volatility
Evenly matched — JPM and CME each lead in 1 of 2 comparable metrics.
Risk & Volatility
CME is the less volatile stock with a -0.30 beta — it tends to amplify market swings less than JPM's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 93.4% from its 52-week high vs MKTX's 63.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.28x | 1.00x | 0.33x | -0.30x |
| 52-Week HighHighest price in past year | $232.84 | $337.25 | $189.35 | $329.16 |
| 52-Week LowLowest price in past year | $148.47 | $248.83 | $143.17 | $257.17 |
| % of 52W HighCurrent price vs 52-week peak | +63.9% | +93.4% | +81.0% | +87.6% |
| RSI (14)Momentum oscillator 0–100 | 28.9 | 53.4 | 42.0 | 41.7 |
| Avg Volume (50D)Average daily shares traded | 443K | 8.4M | 3.1M | 2.2M |
Analyst Outlook
Evenly matched — JPM and ICE and CME each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MKTX as "Hold", JPM as "Buy", ICE as "Buy", CME as "Hold". Consensus price targets imply 31.4% upside for MKTX (target: $196) vs 7.6% for JPM (target: $339). For income investors, CME offers the higher dividend yield at 3.79% vs ICE's 1.26%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $195.60 | $338.78 | $195.71 | $320.25 |
| # AnalystsCovering analysts | 23 | 61 | 36 | 35 |
| Dividend YieldAnnual dividend ÷ price | +2.0% | +1.6% | +1.3% | +3.8% |
| Dividend StreakConsecutive years of raises | 11 | 14 | 14 | 6 |
| Dividend / ShareAnnual DPS | $2.99 | $5.13 | $1.93 | $10.92 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.4% | +3.4% | +1.6% | +0.3% |
JPM leads in 2 of 6 categories (Valuation Metrics, Total Returns). CME leads in 1 (Income & Cash Flow). 2 tied.
MKTX vs JPM vs ICE vs CME: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MKTX or JPM or ICE or CME a better buy right now?
For growth investors, JPMorgan Chase & Co.
(JPM) is the stronger pick with 14. 6% revenue growth year-over-year, versus 6. 4% for CME Group Inc. (CME). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MKTX or JPM or ICE or CME?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 15. 9x versus Intercontinental Exchange, Inc. at 26. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 09x versus MarketAxess Holdings Inc. 's 2. 95x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — MKTX or JPM or ICE or CME?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +110. 3%, compared to -62. 8% for MarketAxess Holdings Inc. (MKTX). Over 10 years, the gap is even starker: JPM returned +471. 7% versus MKTX's +37. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MKTX or JPM or ICE or CME?
By beta (market sensitivity over 5 years), CME Group Inc.
(CME) is the lower-risk stock at -0. 30β versus JPMorgan Chase & Co. 's 1. 00β — meaning JPM is approximately -430% more volatile than CME relative to the S&P 500. On balance sheet safety, MarketAxess Holdings Inc. (MKTX) carries a lower debt/equity ratio of 5% versus 2% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — MKTX or JPM or ICE or CME?
By revenue growth (latest reported year), JPMorgan Chase & Co.
(JPM) is pulling ahead at 14. 6% versus 6. 4% for CME Group Inc. (CME). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 21. 7% year-over-year, compared to 6. 3% for MarketAxess Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MKTX or JPM or ICE or CME?
CME Group Inc.
(CME) is the more profitable company, earning 62. 0% net margin versus 21. 6% for JPMorgan Chase & Co. — meaning it keeps 62. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CME leads at 64. 9% versus 27. 7% for JPM. At the gross margin level — before operating expenses — CME leads at 86. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MKTX or JPM or ICE or CME more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 09x versus MarketAxess Holdings Inc. 's 2. 95x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 2x forward P/E versus 23. 6x for CME Group Inc. — 9. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MKTX: 31. 4% to $195. 60.
08Which pays a better dividend — MKTX or JPM or ICE or CME?
All stocks in this comparison pay dividends.
CME Group Inc. (CME) offers the highest yield at 3. 8%, versus 1. 3% for Intercontinental Exchange, Inc. (ICE).
09Is MKTX or JPM or ICE or CME better for a retirement portfolio?
For long-horizon retirement investors, CME Group Inc.
(CME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 30), 3. 8% yield, +291. 2% 10Y return). Both have compounded well over 10 years (CME: +291. 2%, JPM: +471. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MKTX and JPM and ICE and CME?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MKTX is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; ICE is a mid-cap quality compounder stock; CME is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.